Related Experiment Video

Updated: Jun 13, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy

Huiling Guo1,2, Jianwei Wei3, Yuyan Zhang3

  • 1Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.

Genes & Diseases
|September 10, 2024
PubMed

Insights

Protein ubiquitination impacts ovarian cancer progression and immune response. Combining ubiquitinase/deubiquitinase inhibitors with immunotherapy offers a promising strategy to overcome treatment resistance in ovarian cancer.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Ovarian cancer incidence and mortality are increasing globally.
  • Current treatments like chemotherapy and immunotherapy face challenges with drug resistance and efficacy.
  • Protein ubiquitination, a key post-translational modification, is implicated in cancer development and immune processes.

Purpose of the Study:

  • To review the role of protein ubiquitination in ovarian cancer immunotherapy.
  • To explore advances in using ubiquitinase/deubiquitinase inhibitors combined with immunotherapy for ovarian cancer.

Main Methods:

  • Literature review of studies on protein ubiquitination in ovarian cancer.
  • Analysis of research on ubiquitinase/deubiquitinase inhibitors and cancer immunotherapy.

Main Results:

  • Protein ubiquitination is involved in ovarian cancer progression and tumor immunity.
  • Targeting protein ubiquitination pathways can modulate the tumor immune microenvironment.
  • Combination therapies of ubiquitinase/deubiquitinase inhibitors and immunotherapy show potential to enhance treatment efficacy.

Conclusions:

  • Protein ubiquitination plays a critical role in ovarian cancer immunotherapy.
  • Ubiquitinase/deubiquitinase inhibitors represent a promising therapeutic avenue when combined with immunotherapy to combat ovarian cancer treatment resistance.
Keywords:
DeubiquitinationImmune-related moleculesImmunotherapyOvarian cancerUbiquitination

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.2K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

1.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K